289
Participants
Start Date
November 15, 2013
Primary Completion Date
March 31, 2016
Study Completion Date
March 31, 2016
Graceptor®
oral
Site JP00010, Numakunai
Site JP00001, Aichi
Site JP00015, Chiba
Site JP00003, Ehime
Site JP00029, Fukuoka
Site JP00009, Fukushima
Site JP00017, Gifu
Site JP00002, Hiroshima
Site JP00005, Hokkaido
Site JP00024, Hyōgo
Site JP00012, Ibaraki
Site JP00020, Ishikawa
Site JP00026, Kagawa
Site JP00030, Kagoshima
Site JP00014, Kanagawa
Site JP00027, Kochi
Site JP00028, Kumamoto
Site JP00008, Kyoto
Site JP00019, Mie
Site JP00011, Miyagi
Site JP00006, Nagasaki
Site JP00023, Nara
Site JP00013, Niigata
Site JP00025, Okayama
Site JP00022, Osaka
Site JP00016, Saitama
Site JP00018, Shizuoka
Site JP00007, Tokyo
Site JP00021, Wakayama
Site JP00004, Yamagata
Lead Sponsor
Astellas Pharma Inc
INDUSTRY